Why One Hedge Fund Simply Put $246 Million Into This Life Sciences Provider

New York Metropolis-based Engine Capital Administration purchased 14.2 million shares of Avantor within the third quarter.
The place worth elevated by $172 million from the prior interval.
Submit-transaction, the fund reported holding about 19.7 million Avantor shares valued at $246.1 million, making it Engine’s largest holding as of September 30.
These 10 shares might mint the subsequent wave of millionaires ›

New York Metropolis-based Engine Capital Administration disclosed a purchase of 14.2 million shares of Avantor (NYSE:AVTR), rising its stake by an estimated $172 million within the third quarter, per a November 14 SEC submitting.

In response to a Securities and Trade Fee (SEC) submitting dated November 14, Engine Capital Administration, LP elevated its place in Avantor (NYSE:AVTR) by 14.2 million shares throughout the third quarter. The worth of this stake grew by roughly $172 million, leading to a post-trade holding valued at $246.1 million as of September 30.

Avantor now represents 29.2% of Engine Capital Administration’s 13F AUM.

High holdings after the submitting:

NYSE: AVTR: $246.1 million (29.2% of AUM)
NYSE: NATL: $94.7 million (11.2% of AUM)
NASDAQ: LNW: $80.9 million (9.6% of AUM)
NASDAQ: ACHC: $64.0 million (7.6% of AUM)
NASDAQ: OFIX: $62.3 million (7.4% of AUM)

As of Friday, shares had been priced at $10.93, down 48% over the previous yr and vastly underperforming the S&P 500, which is up 13% in the identical interval.

Metric	Worth
Value (as of market shut Friday)	$10.93
Market Capitalization	$7.5 billion
Income (TTM)	$6.6 billion
Internet Earnings (TTM)	($82.2 million)

Avantor supplies high-purity chemical substances, laboratory provides, single-use assemblies, chromatography resins, analytical kits, and specialised instrumentation for the life sciences and superior know-how sectors.
The corporate generates income by the sale of consumables, tools, and companies, together with laboratory and manufacturing help, procurement, and biopharmaceutical growth options.
Major clients embrace biopharmaceutical producers, healthcare suppliers, tutorial and authorities analysis establishments, and superior know-how firms worldwide.

Avantor, Inc. is a world provider of mission-critical services and products supporting biopharma, healthcare, training, and superior know-how industries. The corporate leverages a broad portfolio and built-in provide chain to serve complicated buyer wants throughout a number of areas. Its scale, numerous choices, and concentrate on high-growth finish markets place Avantor as a key companion for organizations engaged in scientific analysis and manufacturing.

Avantor’s deep drawdown has created a setup long-term traders know effectively: Structurally necessary companies can fall out of favor lengthy earlier than fundamentals stabilize. That stress—between cyclical weak spot and long-term relevance—is central to why this transfer issues. Engine Capital’s elevated focus alerts conviction that Avantor’s portfolio of mission-critical lab and manufacturing provides stays indispensable at the same time as the corporate works by operational missteps and a challenged demand backdrop.

The newest quarter underscored that reset. Internet gross sales fell 5% to $1.6 billion, whereas a $785 million non-cash goodwill impairment drove a GAAP internet lack of $712 million. Nonetheless, adjusted EBITDA of $268 million and free money circulation of $172 million present the enterprise continues to generate significant money, bucking the cruel headline print. Administration additionally licensed a $500 million share repurchase, a notable sign of confidence in future money era and execution progress.

Inside Engine Capital’s portfolio, Avantor now represents a dominant 29.2% weighting—far bigger than its next-largest holding—suggesting the fund views the selloff as misaligned with long-term worth. For affected person traders, the setup resembles a traditional restoration wager: sturdy end-market publicity, enhancing inside self-discipline, and a valuation reset pushed extra by sentiment than solvency.

13F: A quarterly SEC submitting required from institutional funding managers to reveal their fairness holdings.
Belongings Below Administration (AUM): The overall market worth of investments managed on behalf of shoppers by a fund or agency.
Place: The quantity of a selected safety or asset owned by an investor or fund.
Holding: A selected funding owned inside a portfolio or fund.
Reportable Belongings: Investments that have to be disclosed in regulatory filings, such because the 13F report.
Submit-trade: The state of a portfolio or place after a transaction has been accomplished.
Purchase (in fund context): The acquisition of further shares or securities to extend a fund’s publicity to an funding.
Lagging: Underperforming in comparison with a benchmark or index over a given interval.
Biopharmaceutical: Regarding medication produced utilizing biotechnology, usually for medical or therapeutic use.
Consumables: Merchandise which are used up and want common substitute, resembling laboratory provides.
Single-use assemblies: Pre-assembled, disposable elements utilized in manufacturing or laboratory processes to scale back contamination threat.
TTM: The 12-month interval ending with the latest quarterly report.

Ever really feel such as you missed the boat in shopping for probably the most profitable shares? You then’ll need to hear this.

On uncommon events, our knowledgeable group of analysts points a “Double Down” inventory advice for firms that they assume are about to pop. For those who’re frightened you’ve already missed your likelihood to take a position, now’s one of the best time to purchase earlier than it’s too late. And the numbers communicate for themselves:

Nvidia: in the event you invested $1,000 after we doubled down in 2009, you’d have $473,121!*
Apple: in the event you invested $1,000 after we doubled down in 2008, you’d have $53,035!*
Netflix: in the event you invested $1,000 after we doubled down in 2004, you’d have $540,587!*

Proper now, we’re issuing “Double Down” alerts for 3 unimaginable firms, out there whenever you be part of Inventory Advisor, and there will not be one other likelihood like this anytime quickly.

See the three shares »

*Inventory Advisor returns as of December 1, 2025

Jonathan Ponciano has no place in any of the shares talked about. The Motley Idiot has positions in and recommends Mild & Surprise Inc. The Motley Idiot has a disclosure coverage.

Why One Hedge Fund Simply Put $246 Million Into This Life Sciences Provider was initially revealed by The Motley Idiot